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Aim: Patients with hip fractures are often frail with multiple
comorbidities and at risk of medical serious adverse events
(SAEs). We investigated the HEALTH trial patient population to
ascertain predictors of SAEs.
Methods: We performed a multivariable Cox regression analysis.
Occurrence of SAEs was included as the dependent variable with
31 potential prognostic factors being included as independent
variables.
Results: One thousand four hundred forty-one patients were
included in this analysis. Three hundred seventy (25.6%) patients
suffered from an SAE. The most common events were cardiac
(38.4%, n = 105), respiratory (20.8%, n = 77), and neurological
(14.1%, n = 77). The majority of SAEs (50.8%, n = 188) occurred
in the first 90 days after hip fracture with 35.4% occurring in the first
30 days (n = 131). Body mass index (BMI) between 18.5 and 24.9
compared with BMI between 25 and 29.9 [hazard ratio (HR) 1.32, P
= 0.03] and receiving a total hip arthroplasty compared with a bipo-
lar hemiarthroplasty (HR 1.36, P = 0.03) were associated with a
higher risk of a medical SAE within 24 months of femoral neck
fracture. Age (P = 0.09), use of femoral cement (P = 0.59), and
use of canal pressurization (P = 0.37) were not associated with a
medical SAE.
Conclusion: Total hip arthroplasty is associated with more SAEs
in the immediate postoperative period, and care should be taken in
selecting patients for this treatment compared with a hemiarthro-
plasty. A higher BMI may be protective in hip fracture patients while
age alone does not predict SAEs and neither does the use of femoral
cement and/or pressurization.
Key Words: serious adverse events, displaced femoral neck fracture,
total hip arthroplasty, hemiarthroplasty
Level of Evidence: Prognostic Level II. See Instructions for
Authors for a complete description of levels of evidence.
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INTRODUCTION
Elderly patients with hip fractures are often frail with
multiple medical comorbidities and are at risk of suffering
from medical serious adverse events (SAEs). Although the
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definitive treatment for hip fracture is surgical, medical
comorbidities, as well as advancing age, have historically
been reported to increase the risk of death after hip fracture.1–3
The ability to more accurately predict medical SAEs in this
patient group would be a useful tool for the surgeon to
guide clinical decision making regarding the most appropriate
surgical treatment for each individual.
The primary objective of this secondary analysis was to
determine the factors predictive of medical SAEs in patients
from the HEALTH trial aged 50 years or older who were
treated with either hemiarthroplasty or total hip arthroplasty
after a femoral neck fracture.4,5 The secondary objectives
were to determine the timing of the medical SAEs and to
determine the proportion of medical SAEs that occurred after
a fracture-related complication or revision surgery.
METHODS
Medical SAEs were diagnosed by physicians at the
clinical sites and documented during the course of the
HEALTH trial.4,5 An SAE was defined as any adverse event
that was fatal, life-threatening, required or prolonged hospital
stay, resulted in persistent or significant disability or incapacity,
a congenital anomaly or birth defect, or an important medical
event, symptom, sign, illness, or experience that developed or
worsened in severity during the study. SAEs included neuro-
logical, respiratory, cardiac, renal, vascular, multiorgan failure,
sepsis, anemia and other blood issues, dehydration, gastroin-
testinal (GI) bleed, ulcer, other GI problems, and prolonged
hospitalization. Mortality itself was not considered an SAE.
For the purposes of this secondary analysis, we did not con-
sider any fracture-related complications as medical SAEs.
In this secondary analysis, we presented the overall
incidence of medical SAEs that occurred in the HEALTH
trial, the timing of the SAEs (0–30 days after fracture, 31–60
days after fracture, 61–90 days after fracture, and .90 days
after fracture), the incidence of medical SAEs that occurred
after a fracture-related complication, and the incidence of
medical SAEs that occurred after a revision surgery.
Fracture-related complications were defined as compli-
cations related to the hip fracture and initial surgery as per the
original HEALTH trial, such as periprosthetic fracture, hip
instability or dislocation, implant failure (loosening/
subsidence and breakage), wound-healing problems (includ-
ing superficial/deep infection, wound necrosis), another soft-
tissue procedure, clinically important heterotopic ossification,
abductor failure, implant wear and corrosion, osteolysis,
neurovascular injury, decreased function, and pain.
Revision surgery was defined as per the original
HEALTH trial as any unplanned secondary procedure to
treat a fracture-related complication, such as closed and open
reductions of a hip dislocation, open reduction of a fracture,
full or partial implant exchange, implant removal, implant
adjustment, soft-tissue procedure, excision of heterotopic
ossification, insertion of an antibiotic spacer, and other events
as determined by an independent central adjudication
committee.
We also performed a multivariable Cox regression to
determine factors predictive of medical SAEs within 24
months of initial surgery in the HEALTH trial. Our outcome
was a single composite measure which included any type of
medical SAE within 24 months of initial surgery in the
HEALTH trial. Thirty-one prognostic factors were included
as the independent variables and were selected based on
biological rationale, previous literature, and expert opinion.
These factors included the variables used in the minimization
allocation process for the HEALTH trial: age, prefracture
living setting (institutionalized or not institutionalized),
prefracture functional status (using assistive device for
ambulation or able to ambulate without assistive device),
and American Society of Anesthesiologists (ASA) class (class
I/II or III/IV/V). For these covariates, we used values that
were entered into the minimization system at the time of
enrollment. Regression results were presented as hazard ratios
(HRs) with 95% confidence intervals (CIs), and P values. All
tests were 2-tailed with alpha = 0.05. Statistical analysis was
conducted using R (version 3.6.1, R Foundation for Statistical
Computing, Vienna, Austria).
RESULTS
In the HEALTH trial, 1441 patients were randomized to
treatment. At 24 months, 1243 patients were living, and
complete follow-up was achieved for 1058 (85.1%). In the 24
months after hemiarthroplasty and total hip arthroplasty
treatment for femoral neck fracture, there was an overall
25.6% incidence of medical SAEs (n = 370). The incidence of
the various SAEs are summarized in Table 1. The timing of
medical SAEs is summarized in Table 2. The majority
(50.8%, n = 188) occurred in the first 90 days after fracture.
The most common events were cardiac (38.4%, n = 105),
respiratory (20.8%, n = 77), and neurological (14.1%, n = 52).
For patients with fracture-related complications, respi-
ratory and neurological were equally the most common SAE
observed (53.8% n = 14). There were equal cases of cardiac,
neurological, renal, vascular, sepsis, and other GI problem
SAEs (81.8% n = 18) in patients undergoing revision surgery.
The incidence of SAEs after fracture-related complications
and revision surgery is summarized in Tables 3 and 4,
respectively.
Body mass index (BMI) between 18.5 and 24.9 as
compared to a BMI 25–29.9 (HR 1.32, 95% CI 1.03–1.70; P
= 0.03), receiving a total hip arthroplasty as compared to
receiving a bipolar hemiarthroplasty (HR 1.36, 95% CI
1.03–1.81; P = 0.03), not using preoperative traction (HR
1.89, 95% CI 1.18–3.03; P , 0.01), ASA classification class
III/IV/V as compared to class I/II (HR 1.70, 95% CI 1.32–
2.19; P , 0.001), receiving treatment for lung disease (HR
1.52, 95% CI 1.14–2.03; P = 0.004), receiving treatment for
anemia or another blood disease (HR 1.95, 95% CI 1.30–
2.95; P = 0.001), not receiving treatment for ulcers or stom-
ach disease (HR 1.54, 95% CI 1.02–2.32; P = 0.04), receiving
treatment for kidney disease (HR 1.58, 95% CI 1.0–2.42; P =
0.04), receiving treatment for heart disease (HR 1.30, 95% CI
1.03–1.65; P = 0.03), baseline use of steroids (HR 1.70, 95%
CI 1.09–2.63; P = 0.02), preoperative thromboprophylaxis
(HR 1.58, 95% CI 1.21–2.05; P , 0.01), anterolateral/
lateral surgical approach as compared to posterior/
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posterolateral (HR 1.65, 95% CI 1.27–2.16; P , 0.01),
and revision surgery (HR 9.89, 95% CI 5.96–16.4; P ,
0.01) were associated with a higher risk of a medical SAE
within 24 months of femoral neck fracture. Age (P = 0.09),
use of femoral cement (P = 0.59), and use of canal pres-
surization (P = 0.37) were not associated with a medical
SAE. Table 5 summarizes the predictors of SAEs in this
patient group.
DISCUSSION
Our subanalysis of the HEALTH trial data has shown
an overall incidence of medical SAE after hip fracture to be
25.6%. The most common type of medical SAE in this patient
group was cardiac (38.4% n = 105), followed by respiratory
(20.8% n = 77), and neurological (14.1% n = 52). For patients
with fracture-related complications, respiratory and neurolog-
ical SAEs were most commonly observed (each 26.3% n = 5).
However, vascular SAE was the most common (20% n = 6) in
patients undergoing revision surgery. Receiving a total hip
arthroplasty was associated with an increased rate of SAEs
compared with receiving a bipolar hemiarthroplasty. The
patient groups for these interventions were randomized as
per the HEALTH trial methodology, so we believe that this
finding is accurate and could be used to guide practice. This
could be attributed to the acetabular reaming and implantation
or due to the longer operative time and larger physiological
insult to the patient; however, we did not see any effect of
length of surgery or intraoperative blood loss on postopera-
tive SAEs when analyzed independently.
TABLE 1. Overall Incidence of Medical SAEs Within the 24 Months After Arthroplasty
Type of Serious Medical Event Total Incidence, N = 1,441, n (%)
Incidence in the THA Group, N =
718, n (%)
Incidence in the HA Group, N =
723, n (%)
Cardiac 105 (7.3) 53 (7.4) 52 (7.2)
Respiratory 77 (5.3) 42 (5.9) 35 (4.8)
Neurological 52 (3.6) 27 (3.8) 25 (3.5)
Renal 43 (3.0) 23 (3.2) 20 (2.8)
Vascular 38 (2.6) 22 (3.1) 16 (2.2)
Sepsis 17 (1.2) 9 (1.3) 8 (1.1)
GI bleed 11 (0.8) 5 (0.7) 6 (0.8)
Other GI problem 10 (0.7) 6 (0.8) 4 (0.6)
Multiorgan failure 5 (0.3) 1 (0.1) 4 (0.6)
Dehydration 4 (0.3) 2 (0.3) 2 (0.3)
Anemia 3 (0.2) 1 (0.1) 2 (0.3)
Other blood issue 2 (0.1) 1 (0.1) 1 (0.1)
Ulcer 2 (0.1) 2 (0.3) 0 (0.0)
Prolonged hospitalization 1 (0.1) 0 (0.0) 1 (0.1)
GI, gastrointestinal; HA, hemiarthroplasty; THA, total hip arthroplasty.
TABLE 2. Timing of Incidence of Medical SAEs After Arthroplasty
Type of Serious Medical
Event
0–30 Days After
Fracture, N = 131, n (%)
31–60 Days After
Fracture, N = 35, n (%)
61–90 Days After
Fracture, N = 22, n (%)
.90 Days After
Fracture, N = 182, n (%)
Cardiac 44 (33.6) 7 (20.0) 4 (18.2) 50 (27.5)
Respiratory 24 (18.3) 9 (25.7) 6 (27.3) 38 (20.9)
Neurological 14 (10.7) 5 (14.3) 3 (13.6) 30 (16.5)
Vascular 17 (13.0) 6 (17.1) 3 (13.6) 12 (6.6)
Renal 13 (9.9) 4 (11.4) 3 (13.6) 23 (12.6)
GI bleed 7 (5.3) 0 (0.0) 0 (0.0) 4 (2.2)
Multiorgan failure 3 (2.3) 0 (0.0) 0 (0.0) 2 (1.1)
Sepsis 3 (2.3) 3 (8.6) 2 (9.1) 9 (5.0)
Anemia 2 (1.5) 0 (0.0) 0 (0.0) 1 (0.6)
Prolonged hospitalization 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0)
Other blood issue 1 (0.8) 0 (0.0) 1 (4.5) 0 (0.0)
Ulcer 1 (0.8) 0 (0.0) 0 (0.0) 1 (0.6)
Other GI problem 1 (0.8) 1 (2.9) 0 (0.0) 8 (4.4)
Dehydration 0 (0.0) 0 (0.0) 0 (0.0) 4 (2.2)
GI, gastrointestinal.
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There has been a recent trend in using total hip
replacement over hemiarthroplasty for treatment of neck of
femur fractures due to reported improved functional out-
comes,6 despite the reported higher dislocation rate.7–9 Most
studies of this nature record complications related to the oper-
ation such as hip dislocation or revision surgery,10 but few
large scale studies have recorded medical SAEs related to this
patient group. Hansson et al11 looked at 664 hip fracture
patients and recorded pneumonia and additional falls as the
most common complication but did not group the patients by
operation.
The use of a laterally based approach was associated
with an increased risk of SAEs compared with posterior
approaches. This may have been due to selection bias because
even hip fracture surgeons who favor the posterior approach
will tend to use the anterolateral approach for hip fracture
surgery in the frailer patient due to the reported lower
dislocation rate. The National Institute for Clinical
Excellence (NICE) UK guidelines for hip fracture manage-
ment advise surgeons to consider the anterolateral approach in
favor of the posterior approach for hemiarthroplasty12; how-
ever, a recent review of the literature found the evidence too
heterogeneous to make a recommendation.13 The draft NICE
evidence review for approaches in total hip arthroplasty from
October 2019 does not make any recommendations to favor
one approach over the other, but the committee agreed that
the surgeon undertaking the approach must have experience
and competence in that particular approach to get consistently
TABLE 3. Incidence of Medical SAEs after Fracture-Related Complications
Type of Serious Medical Event
No Fracture-Related
Complication, N = 339, n (%)
Fracture-Related Complication*, N
= 26, n (%)
Cardiac 100 (29.5) 3 (11.5)
Respiratory 69 (20.4) 7 (26.9)
Neurological 44 (13.0) 7 (26.9)
Renal 42 (12.4) 1 (3.8)
Vascular 35 (10.3) 3 (11.5)
Sepsis 16 (3.4) 1 (3.8)
GI bleed 10 (3.0) 1 (3.8)
Other GI problem 10 (3.0) 0 (0.0)
Multiorgan failure 5 (1.5) 0 (0.0)
Dehydration 4 (1.2) 0 (0.0)
Ulcer 2 (0.6) 0 (0.0)
Anemia 1 (0.3) 1 (3.8)
Prolonged hospitalization 1 (0.3) 0 (0.0)
Other blood issue 0 (0.0) 2 (7.7)
*Total N is less than 370 because 5 participants experienced a medical SAE before their fracture-related complication.
GI, gastrointestinal.
TABLE 4. Incidence of Medical SAEs After Revision Surgery
Type of Serious Medical Event
No Revision Surgery, N = 314, n
(%) Revision Surgery, N = 22, n (%)
Cardiac 93 (29.6) 3 (13.6)
Respiratory 68 (21.7) 2 (9.1)
Neurological 46 (14.6) 3 (13.6)
Renal 37 (11.8) 3 (13.6)
Vascular 28 (8.9) 3 (13.6)
Sepsis 13 (4.1) 3 (13.6)
GI bleed 8 (2.5) 1 (4.3)
Other GI problem 7 (2.2) 3 (13.6)
Multiorgan failure 5 (1.6) 0 (0.0)
Dehydration 4 (1.3) 0 (0.0)
Anemia 2 (0.6) 0 (0.0)
Ulcer 2 (0.6) 0 (0.0)
Other blood issue 1 (0.3) 1 (4.3)
Prolonged hospitalization 0 (0.0) 0 (0.0)
Total N is less than 370 because 34 participants experienced a medical SAE before their revision surgery.
GI, gastrointestinal.
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good results.14 However, there is a randomized controlled
trial of 500 participants underway that is comparing the direct
lateral versus posterolateral approach for hemiarthroplasty to
answer this question.15
The use of bone cement in the treatment of hip fractures
has created concerns16 due to bone cement implantation syn-
drome.17 This study adds to the existing weight of evidence18
that the use of bone cement is safe in hip fracture surgery.
Despite the higher risk patient population, pressurization of
the canal and the use of femoral or acetabular cement was not
associated with an increased rate of SAEs.
Interestingly, using preoperative skin traction seemed to
lower the incidence of medical SAEs. This could be due to
traction delivering better pain control for these patients and
reducing the risk of fat embolism due to less movement at the
fracture site. However, few institutions in the HEALTH trial
used preoperative traction, so this finding could be attribut-
able to sampling bias.
Treatment for existing medical conditions, such as lung
disease, heart disease, diabetes, anemia, and the use of
steroids, was all associated with an increased risk of SAEs.
This correlates with clinical practice and existing studies.19,20
A higher ASA grade was associated with an increased risk of
SAEs. Smith et al conducted a meta-analysis of studies
TABLE 5. Factors Associated With a Medical SAE (n = 1,244,
368 Events)
Variable HR (95% CI) P
BMI (kg/m2)
,18.5 vs. 25–29.9 1.58 (0.99–2.52) 0.055
18.5–24.9 vs. 25–29.9 1.32 (1.03–1.70) 0.03
$30 vs. 25–29.9 0.97 (0.67–1.42) 0.88
ASA classification
Class III/IV/V vs. Class I/II 1.70 (1.32–2.19) ,0.001
Patient receiving treatment for lung
disease
Yes vs. no 1.52 (1.14–2.03) 0.004
Patient receiving treatment for
anemia or another blood disease
Yes vs. no 1.95 (1.30–2.95) 0.001
Patient receiving treatment for ulcers
or stomach disease
No vs. yes 1.54 (1.02–2.32) 0.04
Patient receiving treatment for kidney
disease
Yes vs. no 1.58 (1.03–2.42) 0.04
Patient receiving treatment for heart
disease
Yes vs. no 1.30 (1.03–1.65) 0.02
Baseline use of steroids
Yes vs. no 1.70 (1.09–2.63) 0.02
Preoperative traction
No vs. yes 1.89 (1.18–3.03) 0.02
Preoperative thromboprophylaxis
Yes vs. no 1.58 (1.21–2.05) ,0.01








Total hip arthroplasty vs. bipolar
hemiarthroplasty
1.36 (1.03–1.81) 0.03
Total hip arthroplasty vs.
monopolar hemiarthroplasty
1.34 (0.97–1.85) 0.08
Revision surgery before medical SAE
Yes vs. no 9.89 (5.96–16.4) ,0.01






Use of walking aid vs. independent
ambulator
1.03 (0.80–1.31) 0.82
Patient receiving treatment for cancer
Yes vs. no 1.19 (0.76–1.88) 0.45
Patient receiving treatment for
rheumatoid arthritis
Yes vs. no 0.50 (0.18–1.36) 0.17
Patient receiving treatment for
diabetes
Yes vs. no 1.30 (0.98–1.72) 0.07
TABLE 5. (Continued ) Factors Associated With a Medical SAE
(n = 1,244, 368 Events)
Variable HR (95% CI) P
Patient receiving treatment for
depression
Yes vs. no 0.81 (0.54–1.21) 0.31
Baseline use of opioid medications
Yes vs. no 0.93 (0.61–1.40) 0.74
Time from injury to surgery (h) 0.998 (0.996–1.002) 0.07
Additional injuries
Yes vs. no 0.94 (0.51–1.74) 0.86
Length of surgery (min) 1.001 (0.998–1.003) 0.50
Type of anesthesia
Regional/other vs. general 1.23 (0.96–1.57) 0.10
Intraoperative blood loss (mL) 1.001 (0.999–1.002) 0.27
Use of femoral cement
Yes vs. no 1.17 (0.64–2.14) 0.59
Use of canal pressurization as
cementing technique
1.30 (0.72–2.34)
Yes vs. no 0.37
Femoral canal prepared with
pulsatile lavage
0.67 (0.45–1.003)
Yes vs. no 0.051
Use of acetabular cement 0.77 (0.55–1.09)
Yes vs. no 0.14
Fracture-related complication before
medical SAE
Yes vs. no 1.46 (0.45–4.70) 0.52
ASA, American Society of Anesthesiologists; BMI, body mass index; CI,
confidence interval; HR, hazard ratio; SAE, serious adverse event.
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looking at preoperative indicators for mortality after hip frac-
ture surgery. Four studies with a total of 1559 participants
were included assessing risk of death based on ASA grade
and found that patients with an ASA grade of 3 or 4 were at a
44% increased risk of death at 12 months compared to those
with a grade of 1 or 2.21 The Hailer et al22 review using the
Swedish joint register investigated 24,699 patients who had
undergone total hip arthroplasty for neck of femur fracture
and found that 90-day mortality was significantly higher in
patients with ASA 3 compared with ASA 1 (HR = 9.5).
Another interesting finding of the subanalysis was that
age alone does not predict medical SAEs and neither does
prefracture functional or living status. Schnell et al23 reported
patient demographics and outcomes of 758 patients treated in
their program over a 4-year period. They showed that 1-year
mortality was highest for patients who were older than 90
years compared with those 70–79 or 80–89 years of age;
however, they did not specifically report on the incidence
of SAEs. Although it is logical that older hip fracture patients
are less likely to survive at 1 year compared with younger
patients, age does not seem to predict medical SAEs. This
may be a result of the patients who are living to an older age
before sustaining a hip fracture having less medical comor-
bidities, and in clinical practice, it is often the case that the
older hip fracture patient is “fitter.”
A higher BMI may be protective for medical SAEs in
hip fracture patients. The CDC (Centers for Disease Control
and Prevention) categorize BMI into 4 universal categories
—,18.5 underweight, 18.5–24.9 normal weight, 25–29.9
overweight, and .30 obese.24 Sherrif et al reviewed the
National Surgical Quality Improvement Program database
for hip fracture patients, and of the 15,108 patients, they
found that patients with very low BMI had a higher mortality
rate than patients with a very high BMI, but that those at the
extreme ends of the BMI spectrum suffered the most compli-
cations. Transfusion rates were observed to decrease as BMI
increased.25
The strength of our study is that the data used here are
sourced from a large-scale trial which had broad inclusion
criteria. Recruitment also occurred from a large number of
hospitals in diverse health care systems, therefore, giving a
more accurate view of SAEs in hip fracture patients
encountered in day-to-day practice, as well as increasing the
generalizability of the external validity of our findings.
A limitation of our subanalysis is the loss of patients over
the 24 months of follow-up in the original study (14.9%).
However, the loss to follow-up was consistent with or better
than other trials including hip fracture patients.25 The
HEALTH trial had unavoidable variables across the patient
group, such as patient positioning, surgical exposure, use of
traction, type of anesthetic, and physiotherapy and rehabilita-
tion protocols, which may have affected results. Finally, as the
data used here were from subanalysis of another trial, there is
not as detailed information collected on each SAE, than if it
had been a trial designed with SAE as the primary outcome.
In conclusion, total hip arthroplasty is associated with
more SAEs than hemiarthroplasty and care should be taken in
selecting patients for this treatment. Cement does not increase
the incidence of SAEs, and clinicians should remain confident
to use this technique when appropriate. Age alone is not a
predictor of medical SAEs; therefore, each hip fracture patient
should receive individualized care. We hope that the findings
of this subanalysis can aid the clinician when deciding the
most appropriate surgical treatment for this vulnerable group.
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